The global Integrase Inhibitors Market is estimated to be valued at US$ 29.34 Bn in 2023 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Integrase inhibitors are a class of antiretroviral drugs used in highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1 infection. Integrase inhibitors work by binding to the HIV integrase enzyme and blocking it from integrating the viral DNA genome into the DNA of the infected human cell. They help suppress the ability of the virus to reproduce and spread to other cells. Some key benefits of integrase inhibitors include achieving high viral suppression, high genetic barrier to drug resistance, favorable tolerability and safety profile, less drug interactions, and once-daily dosing. Growing prevalence of HIV around the world and increasing adoption of integrase inhibitors over other drug classes are majorly driving the growth of this market.
Market key trends:
One of the key trends in the integrase inhibitors market is the introduction of long-acting injectable formulations. Long-acting injectables provide less frequent dosing which helps improve patient adherence to treatment. In July 2021, Cabenuva, a monthly long-acting dual regimen of cabotegravir and rilpivirine, was approved by the U.S FDA for treatment of HIV-1 infection in virologically suppressed adults. Additionally, research is ongoing to develop integrase inhibitors with better potency and efficacy against mutant strains of HIV. Development of newer drug delivery systems such as nanoformulations is also gaining attention to enhance drug bioavailability and sustained release. These technological advancements are expected to significantly expand the therapeutic applications of integrase inhibitors in the upcoming years.
Porter's Analysis
Threat of new entrants: The threat of new entrants is low due to the costly process needed for research and development of AIDS drugs. Any new entrant needs to invest substantial capital to comply with strict regulations.
Bargaining power of buyers: The bargaining power of buyers is high as integrase inhibitors are not significantly differentiated and switching costs are low for buyers. This forces companies to compete on pricing and service.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the availability of substitutes and less concentration of suppliers in the market.
Threat of new substitutes: Threat of new substitutes is moderate as companies invest heavily in R&D and intellectual property protection to protect their drugs from new substitutes. However, patents eventually expire opening opportunities.
Competitive rivalry: The competitive rivalry in the integrase inhibitors market is high due to the presence of many global generic and branded drug makers.
Key Takeaways
Global Integrase Inhibitors Market Size is expected to witness high growth, exhibiting CAGR of 3.9% over the forecast period, due to increasing prevalence of HIV/AIDS across the globe. According to UNAIDS, 37.7 million people were living with HIV/AIDS globally in 2020.
Regional analysis: North America dominates the integrase inhibitors market currently due to rising awareness about HIV treatment and well-established healthcare infrastructure. However, Asia Pacific is expected to grow at the fastest rate due to presence of developing economies like China and India with high untreated HIV cases.
Key players: Key players operating in the integrase inhibitors market are Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen, Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd. Gilead Sciences leads the market with its key drug Biktarvy contributing over 50% of the total integrase inhibitors sales globally.
Read More- https://www.ukwebwire.com/integrase-inhibitors-market-value-analysis-and-insights/
